Acute respiratory distress syndrome (ARDS) is a diffuse inflammatory lung injury defined clinically by the Berlin criteria and pathologically by diffuse alveolar damage (DAD). Its pharmacological management is largely supportive, but lung-protective ventilation and adjunctive corticosteroids have demonstrated mortality benefit in appropriately selected patients and constitute the pharmacological core of ARDS management.
The Berlin definition of acute respiratory distress syndrome (ARDS), published by the ARDS Definition Task Force in 2012, categorizes ARDS by severity based on the ratio of partial pressure of arterial oxygen (PaO2) to fraction of inspired oxygen (FiO2) measured with at least 5 cmH2O of positive end-expiratory pressure (PEEP): mild ARDS is a PaO2/FiO2 ratio of 201 to 300 mmHg, moderate ARDS is 101 to 200 mmHg, and severe ARDS is 100 mmHg or below.1 The bilateral chest imaging infiltrates must not be fully explained by effusions, lobar collapse, or nodules, and respiratory failure must not be primarily attributable to cardiac failure or fluid overload. Onset must occur within one week of a known clinical insult. Severity stratifies both the risk of death and the threshold for escalating interventions including neuromuscular blockade (NMB), prone positioning, and rescue vasodilator therapy.
The pathological substrate of ARDS is diffuse alveolar damage (DAD), characterized by flooding of alveoli with protein-rich edema fluid from damaged alveolar-capillary membranes, formation of hyaline membranes composed of fibrin and plasma proteins, loss of surfactant function producing alveolar collapse and reduced pulmonary compliance, and recruitment of neutrophils whose proteases, reactive oxygen species (ROS), and inflammatory cytokines including interleukin-1 beta (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor alpha (TNF-α) perpetuate and amplify the initial injury.2 The resulting lung is heterogeneous: some alveoli are flooded and collapsed, some are recruitable, and some remain aerated. This heterogeneity means that tidal volumes (Vt) sized for the full lung weight preferentially overdistend the aerated regions, compounding injury through a mechanism termed volutrauma, while repetitive alveolar opening and closing in recruitable regions produces atelectrauma.
Lung-protective ventilation with low tidal volume is the cornerstone of ARDS management and the only ventilator strategy with demonstrated mortality benefit. The landmark ARDSNet (Acute Respiratory Distress Syndrome Clinical Network) trial (Brower 2000) randomized 861 patients to Vt of 6 mL per kilogram (kg) of ideal body weight (IBW) with plateau airway pressure (Pplat) limited to 30 cmH2O or less, versus the then-conventional Vt of 12 mL/kg IBW, and demonstrated a 22 percent relative reduction in 28-day mortality in the low-Vt arm.3 Permissive hypercapnia, meaning acceptance of elevated arterial carbon dioxide (PaCO2) levels that result from the reduced minute ventilation of low-Vt ventilation, is intrinsic to this strategy and is tolerated unless contraindicated by elevated intracranial pressure (ICP) or severe metabolic acidosis. PEEP titration to maintain alveolar recruitment while avoiding overdistension is the complementary strategy; optimal PEEP levels vary by individual patient lung mechanics and are guided by compliance curves or empirical PEEP-FiO2 tables.
Corticosteroids have a long and contested history in ARDS pharmacotherapy. The most robust evidence now supports dexamethasone in moderate-to-severe ARDS. The DEXA-ARDS (Dexamethasone for ARDS) trial (Villar 2020) randomized 277 patients with moderate-to-severe ARDS (PaO2/FiO2 at or below 200 mmHg despite optimized ventilation) to dexamethasone 20 mg intravenously (IV) daily for five days followed by 10 mg IV daily for five days, versus placebo, and demonstrated 60-day mortality of 21.1 percent in the dexamethasone arm versus 36.4 percent in the placebo arm, along with significantly more ventilator-free days.4 The proposed mechanism is suppression of the sustained inflammatory phase that perpetuates lung injury beyond the initial insult. Dexamethasone should not be used in ARDS attributable to influenza, where corticosteroids have shown evidence of harm by prolonging viral replication. Methylprednisolone is used in some protocols as an alternative; the multi-dose methylprednisolone approach has also shown benefit in earlier trials but the DEXA-ARDS dexamethasone regimen has the most recent and robust evidence base.
Dexamethasone 20 mg IV daily for 5 days then 10 mg IV daily for 5 days is supported by DEXA-ARDS for moderate-to-severe ARDS (PaO2/FiO2 at or below 200 mmHg). Do not use corticosteroids in influenza-associated ARDS (evidence of harm). Benefit is greatest when initiated in the active inflammatory phase, not as rescue therapy late in the fibroproliferative phase. Ensure adequate source control if sepsis is the precipitant before initiating corticosteroids, and monitor blood glucose closely throughout the course.
The pharmacological management of sedation and analgesia in mechanically ventilated patients has shifted from deep continuous sedation to analgesia-first, light-sedation protocols targeting a defined Richmond Agitation-Sedation Scale (RASS) score. Deep sedation independently increases mortality, prolongs mechanical ventilation, and increases the incidence of post-intensive care syndrome (PICS), including long-term cognitive impairment.
The analgesia-first (analgosedation) paradigm recognizes that pain is the primary driver of agitation in most mechanically ventilated patients and that treating pain first frequently reduces the amount of sedative required. The Richmond Agitation-Sedation Scale (RASS), scored from −5 (unarousable) to +4 (combative), provides a validated bedside tool for targeting sedation depth. The 2018 Pain, Agitation/sedation, Delirium, Immobility, and Sleep disruption (PADIS) guidelines from the Society of Critical Care Medicine (SCCM) recommend targeting a RASS of 0 to −2 (alert to lightly sedated) in most mechanically ventilated patients, with daily sedation interruption (wake-up trial) to reassess neurological status and prevent sedative accumulation.5 Deeper sedation targets (RASS −3 to −5) are reserved for patients with refractory ventilator dyssynchrony, elevated intracranial pressure, or active neuromuscular blockade.
Propofol (2,6-diisopropylphenol) is an IV anesthetic and sedative agent that potentiates gamma-aminobutyric acid type A (GABA-A) receptor-mediated chloride conductance, producing dose-dependent sedation, amnesia, and at higher doses general anesthesia. For intensive care unit (ICU) sedation, propofol is administered as a continuous IV infusion, typically at 5 to 50 micrograms per kilogram per minute (mcg/kg/min), titrated to the RASS target. Its lipophilic nature produces rapid onset within 1 to 2 minutes and rapid offset on discontinuation, making it well suited for daily wake-up trials. The principal safety concern is propofol infusion syndrome (PRIS), a rare but potentially fatal complication characterized by metabolic acidosis, rhabdomyolysis (skeletal muscle breakdown), cardiac arrhythmias including new right bundle branch block, and multiorgan failure; it occurs most commonly with high-dose infusions above 4 to 5 mg/kg/hour sustained for more than 48 hours, particularly in patients receiving concurrent corticosteroids or catecholamines. Propofol is formulated in a 10 percent lipid emulsion providing 1.1 kcal/mL; total caloric delivery from the emulsion must be accounted for in nutrition calculations, and triglyceride levels should be monitored every 48 to 72 hours in patients on sustained high-dose infusions.6
Dexmedetomidine is a highly selective alpha-2 adrenergic receptor (alpha-2 AR) agonist with an alpha-2 to alpha-1 selectivity ratio of approximately 1600:1 that produces sedation by inhibiting norepinephrine (NE) release from locus coeruleus (LC) neurons, generating a state of cooperative, arousable sedation that mimics natural non-rapid eye movement (NREM) sleep. Unlike propofol or benzodiazepines, dexmedetomidine does not suppress respiratory drive at clinical doses, allowing its use in spontaneously breathing and minimally assisted ventilation contexts and during planned extubation. The SEDCOM (Safety and Efficacy of Dexmedetomidine Compared with Midazolam) trial demonstrated more time at RASS target, less delirium, and shorter time to extubation compared with midazolam; additional data from the MENDS (Maximizing Efficacy of Targeted Sedation and Reducing Neurological Dysfunction) trial confirmed reduced delirium and coma-free days versus lorazepam.7 Dexmedetomidine commonly produces bradycardia and hypotension as extensions of its alpha-2 pharmacology; loading doses are frequently omitted in hemodynamically unstable patients.
Midazolam is a short-acting water-soluble benzodiazepine that acts at GABA-A receptors by enhancing chloride channel opening frequency in response to gamma-aminobutyric acid (GABA), producing anxiolysis, amnesia, and sedation. Despite its short elimination half-life, midazolam undergoes hepatic oxidation to 1-hydroxymidazolam, which is further conjugated to 1-hydroxymidazolam glucuronide (1-OHMG), an active metabolite that accumulates in renal impairment and can produce prolonged sedation beyond the infusion rate's prediction. Benzodiazepines as a class are associated with substantially higher rates of delirium compared with dexmedetomidine and propofol and are not recommended as first-line ICU sedatives; lorazepam is reserved for seizure management and alcohol withdrawal, and midazolam for procedural sedation or when alternatives are unavailable.8 Fentanyl is the most commonly used ICU opioid, administered by continuous infusion, chosen for rapid onset and high potency; the analgesia-first protocol targets a numeric rating scale (NRS) pain score of 3 or below before adding or titrating sedatives.
PRIS risk factors: dose above 4–5 mg/kg/hour, duration above 48 hours, concurrent corticosteroids or catecholamines, high metabolic demand. Early features: new metabolic acidosis with elevated anion gap (AG), elevated creatine kinase (CK), new cardiac dysrhythmia, lipemic plasma. Action: stop propofol immediately, switch to alternative sedation, provide cardiovascular support. Prevention: cap propofol at 4 mg/kg/hour when possible and monitor triglycerides every 48–72 hours in high-dose or prolonged use.
Neuromuscular blocking agents (NMBAs) in the intensive care unit (ICU) are used to facilitate lung-protective ventilation in severe acute respiratory distress syndrome (ARDS) by eliminating spontaneous respiratory efforts that produce ventilator dyssynchrony, to reduce oxygen consumption, and to facilitate prone positioning. Their use requires concurrent adequate analgesia and sedation, train-of-four (TOF) monitoring, and strict duration limits to minimize ICU-acquired weakness (ICUAW).
Cisatracurium is the preferred neuromuscular blocking agent (NMBA) for sustained ICU infusion in ARDS. It is a non-depolarizing benzylisoquinolinium NMBA that competitively antagonizes acetylcholine (ACh) at nicotinic acetylcholine receptors (nAChRs) at the neuromuscular junction (NMJ), preventing motor end-plate depolarization and muscle contraction. Its pharmacokinetic advantage in the ICU is organ-independent elimination via Hofmann elimination (spontaneous pH- and temperature-dependent chemical degradation) and plasma esterase hydrolysis, ensuring clearance is not dependent on renal or hepatic function and making it the agent of choice in multiorgan failure. The ACURASYS (Acute Respiratory Distress Syndrome and Cisatracurium Besylate) trial (Papazian 2010) randomized 340 patients with severe ARDS (PaO2/FiO2 below 150 mmHg) to 48 hours of cisatracurium infusion versus placebo with all patients on midazolam-fentanyl sedation, and demonstrated a reduction in 90-day adjusted mortality (31.6% versus 40.7%) and more ventilator-free days.9
The survival benefit of ACURASYS was not replicated in the ROSE (Reevaluation of Systemic Early Neuromuscular Blockade) trial (Moss 2019), which randomized 1006 patients with moderate-to-severe ARDS (PaO2/FiO2 below 150 mmHg) to early cisatracurium infusion versus a light-sedation protocol without routine neuromuscular blockade (NMB), and found no difference in 90-day mortality (42.5% versus 42.8%).10 The ROSE control arm used a substantially higher proportion of dexmedetomidine-based light sedation than ACURASYS, and the better-than-expected control arm outcomes likely reflect the benefit of the light-sedation protocol itself rather than equivalence of NMB. Current practice reserves routine NMB in ARDS for patients with refractory hypoxemia, persistent ventilator dyssynchrony unresolved by optimized sedation, or as a facilitation measure for prone positioning, rather than applying it universally to severe ARDS.
ICUAW (ICU-acquired weakness) is the most clinically significant long-term complication of prolonged NMBA use, affecting a substantial proportion of patients who receive NMBAs for 48 hours or more. The mechanism combines disuse atrophy, corticosteroid-induced myopathy when corticosteroids are co-administered, and critical illness polyneuropathy (CIP) and critical illness myopathy (CIM) driven by the systemic inflammatory and metabolic milieu of critical illness itself. ICUAW produces profound limb and respiratory muscle weakness that can persist for months to years, impairing rehabilitation and quality of life. Prevention strategies include limiting NMBA duration to the clinically necessary minimum, maintaining TOF monitoring targeting one to two twitches out of four (not zero twitches) during infusion, avoiding concurrent corticosteroids where clinically feasible, and initiating early physical therapy once NMB is discontinued.9
Rocuronium is a non-depolarizing aminosteroid NMBA used primarily for rapid-sequence intubation (RSI) in the emergency and ICU setting as an alternative to succinylcholine when succinylcholine is contraindicated (hyperkalemia risk, burn injury, prolonged immobility, known or suspected channelopathy). At 1.2 mg/kg IV, rocuronium produces intubating conditions within 60 to 90 seconds with a duration of 30 to 60 minutes that cannot be reversed by conventional anticholinesterase agents at intubating doses. Sugammadex is a modified gamma-cyclodextrin that encapsulates steroidal NMBAs (rocuronium and vecuronium) in a 1:1 stoichiometric complex, producing immediate reversal of any depth of neuromuscular block within 3 to 5 minutes. Sugammadex 16 mg/kg IV fully reverses a 1.2 mg/kg rocuronium RSI dose within 3 minutes and is the preferred rescue agent in a cannot-intubate, cannot-oxygenate (CICO) scenario when rocuronium was used for induction. Sugammadex does not reverse cisatracurium or succinylcholine.11
Patients receiving continuous NMBA infusions are paralyzed and cannot signal pain or distress. Confirm adequate sedation (RASS −2 to −3 minimum) and analgesia before initiating any NMBA infusion and verify at each assessment interval. Monitor TOF by peripheral nerve stimulation, targeting 1–2 twitches out of 4 during maintenance infusion. TOF of zero indicates excessive block; reduce infusion rate. Document TOF values at minimum every 4 hours. Never leave a paralyzed patient unobserved.
Inhaled pulmonary vasodilators deliver drug preferentially to ventilated alveolar units, where they relax pulmonary vascular smooth muscle and redirect blood flow away from atelectatic, non-ventilated regions toward ventilated regions, reducing intrapulmonary shunt and improving the ventilation-perfusion (V/Q) ratio. This selectivity for ventilated lung units distinguishes inhaled from systemic vasodilators and is the physiological basis for their use as rescue oxygenation strategies in refractory hypoxemia.
Inhaled nitric oxide (iNO) is an endogenous vasodilatory gas that, when delivered by inhalation, diffuses from ventilated alveoli into adjacent pulmonary vascular smooth muscle cells, activates soluble guanylate cyclase (sGC) to produce cyclic guanosine monophosphate (cGMP), and causes selective vasodilation in ventilated lung regions. Its extremely short half-life of approximately 3 to 5 seconds in blood, due to rapid oxidation by oxyhemoglobin to methemoglobin (MetHb) and nitrate, limits its vasodilatory action to the pulmonary vasculature and prevents systemic hypotension. Multiple randomized controlled trials (RCTs) and the Cochrane systematic review by Gebistorf and colleagues (2016) have consistently demonstrated that iNO improves the PaO2/FiO2 ratio by 10 to 25 percent in acute respiratory distress syndrome (ARDS) but does not reduce mortality, duration of mechanical ventilation, or intensive care unit (ICU) length of stay compared with placebo in unselected ARDS patients.12 The oxygenation improvement is typically transient, lasting 24 to 72 hours, due to downregulation of sGC expression in response to sustained cGMP elevation. iNO is therefore used as a rescue bridge in severe refractory hypoxemia (PaO2/FiO2 below 80 to 100 mmHg) while definitive interventions such as prone positioning or extracorporeal membrane oxygenation (ECMO) evaluation are pursued.
The primary toxicity of iNO is methemoglobinemia: iNO oxidizes oxyhemoglobin to methemoglobin, which cannot carry oxygen. At therapeutic doses of 1 to 40 parts per million (ppm), MetHb levels typically remain below 3 percent and are clinically inconsequential, but higher doses or administration in patients with methemoglobin reductase deficiency can produce clinically significant methemoglobinemia. MetHb levels should be monitored every 4 to 8 hours during iNO therapy. Rebound hypoxemia on discontinuation is the second critical safety concern: abrupt withdrawal causes acute pulmonary vasoconstriction from suppression of endogenous nitric oxide (NO) synthase activity that occurs during iNO therapy. iNO must be weaned gradually, with dose reductions of approximately 50 percent every 4 hours per protocol, and oxygenation monitored closely during weaning. Formation of nitrogen dioxide (NO2) from oxidation of iNO in the gas delivery circuit is monitored continuously during administration; NO2 concentrations above 3 ppm are associated with airway toxicity.13
Inhaled epoprostenol (inhaled prostacyclin, iPGI2) produces pulmonary vasodilation by a mechanism distinct from iNO: it activates prostacyclin receptors (IP receptors) on pulmonary vascular smooth muscle to raise cyclic adenosine monophosphate (cAMP), producing vasodilation selectively in ventilated lung units by the same anatomical principle of drug delivery. When delivered by continuous nebulization at typical doses of 0.05 micrograms per kilogram per minute, inhaled epoprostenol produces oxygenation improvements comparable to iNO in ARDS, as demonstrated in multiple observational and small randomized studies. Practical advantages include the absence of specialized delivery infrastructure and substantially lower cost in most healthcare systems. Limitations include a less robust evidence base than iNO and the need for specific nebulizer positioning to prevent aerosol contamination of ventilator expiratory filters. Inhaled epoprostenol is used as a practical iNO alternative, particularly when iNO delivery systems are unavailable or prohibitively expensive, and its physiological effects in terms of V/Q matching and oxygenation improvement are considered equivalent for clinical decision-making in ARDS rescue therapy.12
Multiple large RCTs confirm that iNO does not reduce ARDS mortality. Appropriate use: short-term rescue for severe refractory hypoxemia (PaO2/FiO2 below 80–100 mmHg) as a bridge to prone positioning, ECMO evaluation, or treatment of the precipitating cause. Establish a weaning plan before initiating iNO to avoid abrupt-discontinuation rebound hypoxemia. Monitor MetHb every 4–8 hours and NO2 continuously. Do not use iNO as a substitute for prone positioning, which has demonstrated mortality benefit in severe ARDS.
Weaning from mechanical ventilation has pharmacological determinants that are as clinically important as ventilator settings. The key pharmacological considerations are timely sedation reduction to enable the spontaneous breathing trial (SBT), corticosteroid-based prevention of post-extubation laryngeal edema, and methylxanthines as respiratory stimulants in chronic obstructive pulmonary disease (COPD)-associated weaning failure.
The spontaneous breathing trial (SBT) is the validated clinical tool for assessing readiness for extubation and should be attempted daily in patients who meet predefined readiness criteria. It is performed by switching the patient to minimal ventilator support, typically continuous positive airway pressure (CPAP) at 5 cmH2O or low-level pressure support at 5 to 8 cmH2O, for 30 to 120 minutes, and observing for failure signs including tachypnea above 35 breaths per minute, hypoxemia, accessory muscle use, paradoxical abdominal motion, diaphoresis, agitation, or new arrhythmia. The pharmacological prerequisite for a valid SBT is reduction of sedation and analgesic infusions to allow adequate arousal: Richmond Agitation-Sedation Scale (RASS) score of 0 to −1 is the target at SBT initiation. Residual neuromuscular blockade must be excluded by documenting a train-of-four (TOF) of four out of four twitches and a sustained five-second head-lift or equivalent sustained contraction, or by administering sugammadex reversal if steroidal NMBAs were used.11
Post-extubation laryngeal edema (post-extubation stridor) is caused by mucosal edema of the larynx and subglottis from endotracheal tube (ETT) pressure trauma. It occurs in approximately 10 to 30 percent of patients after prolonged intubation, typically defined as more than 36 to 72 hours, and is a preventable cause of reintubation in patients who otherwise pass an SBT. The cuff leak test, which assesses the volume of gas passing around a deflated ETT cuff, identifies high-risk patients: a small or absent cuff leak volume predicts laryngeal edema. The pharmacological prevention strategy is methylprednisolone 20 mg IV every 4 hours for 4 doses starting 12 hours before planned extubation, supported by the TOP (Treatment of Post-Extubation Stridor) trial (Francois 2007) and subsequent meta-analyses, which demonstrated reductions in post-extubation stridor from approximately 22 percent to 7 percent and reductions in reintubation rates in high-risk patients identified by positive cuff leak test.14 A single dose of dexamethasone is used in some protocols as a simpler alternative, though the multi-dose methylprednisolone protocol has stronger individual trial support for this specific indication.
In patients with COPD (chronic obstructive pulmonary disease) who fail weaning attempts, methylxanthines including theophylline and aminophylline may facilitate extubation through two pharmacological mechanisms distinct from their bronchodilatory effects. First, at plasma concentrations of 8 to 12 mcg/mL (below the bronchodilatory target range), theophylline produces measurable improvement in diaphragmatic contractility and fatigue resistance by mechanisms including phosphodiesterase inhibition with resultant elevation of diaphragmatic muscle cAMP, increasing force generation in fatigued respiratory muscle. The landmark study by Aubier and colleagues (1985) demonstrated that theophylline reversed diaphragmatic fatigue in mechanically ventilated patients with acute respiratory failure and increased transdiaphragmatic pressure generation significantly.15 Second, theophylline exerts a central respiratory stimulant effect via adenosine receptor (A1 and A2A receptor) antagonism in brainstem respiratory centers, increasing respiratory drive and minute ventilation in patients with blunted ventilatory output. The narrow therapeutic window of theophylline, with serious toxicity including tachyarrhythmias, seizures, and nausea occurring above plasma concentrations of 20 mcg/mL, mandates therapeutic drug monitoring at steady state. Aminophylline, the ethylenediamine salt of theophylline containing 80 percent theophylline by weight, is the IV formulation used for acute administration; loading and maintenance doses must be adjusted for prior oral theophylline use to avoid accumulation.
Before each SBT attempt confirm: (1) precipitating cause of respiratory failure addressed or improving; (2) FiO2 at or below 0.4 with PEEP at or below 8 cmH2O; (3) RASS 0 to −1 after sedation reduction with patient following simple commands; (4) no active NMBA in the prior 4 hours and TOF 4/4 confirmed or sugammadex reversal administered; (5) hemodynamic stability without vasopressor escalation; (6) no active uncontrolled bronchospasm. If SBT fails, identify the specific limiting factor, address it pharmacologically or physiologically, and retry after 24 hours. Do not repeat an SBT on the same day after failure unless the cause was acutely reversible.
ARDS Definition Task Force, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin Definition. JAMA. 2012;307(23):2526–2533.
doi:10.1001/jama.2012.5669Matthay MA, Zemans RL, Zimmerman GA, et al. Acute respiratory distress syndrome. Nat Rev Dis Primers. 2019;5(1):18.
doi:10.1038/s41572-019-0069-0Brower RG, Matthay MA, Morris A, et al. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome. N Engl J Med. 2000;342(18):1301–1308.
doi:10.1056/NEJM200005043421801Villar J, Ferrando C, Martinez D, et al. Dexamethasone treatment for the acute respiratory distress syndrome: a multicentre, randomised controlled trial. Lancet Respir Med. 2020;8(3):267–276.
doi:10.1016/S2213-2600(19)30417-5Devlin JW, Skrobik Y, Gelinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018;46(9):e825–e873.
doi:10.1097/CCM.0000000000003299Diprivan (propofol) prescribing information. Fresenius Kabi USA; 2014. Available at FDA label repository.
Jakob SM, Ruokonen E, Grounds RM, et al. Dexmedetomidine vs midazolam or propofol for sedation during prolonged mechanical ventilation: two randomized controlled trials. JAMA. 2012;307(11):1151–1160.
doi:10.1001/jama.2012.304Barr J, Fraser GL, Puntillo K, et al. Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med. 2013;41(1):263–306.
doi:10.1097/CCM.0b013e3182783b72Papazian L, Forel JM, Gacouin A, et al. Neuromuscular blockers in early acute respiratory distress syndrome. N Engl J Med. 2010;363(12):1107–1116.
doi:10.1056/NEJMoa1005372National Heart, Lung, and Blood Institute PETAL Clinical Trials Network, Moss M, Huang DT, et al. Early neuromuscular blockade in the acute respiratory distress syndrome. N Engl J Med. 2019;380(21):1997–2008.
doi:10.1056/NEJMoa1901686Brueckmann B, Sasaki N, Grobara P, et al. Effects of sugammadex on incidence of postoperative residual neuromuscular blockade: a randomized, controlled study. Br J Anaesth. 2015;115(5):743–751.
doi:10.1093/bja/aev104Gebistorf F, Karam O, Wetterslev J, Afshari A. Inhaled nitric oxide for acute respiratory distress syndrome (ARDS) in children and adults. Cochrane Database Syst Rev. 2016;(6):CD002787.
doi:10.1002/14651858.CD002787.pub3Griffiths MJD, McAuley DF, Perkins GD, et al. Guidelines on the management of acute respiratory distress syndrome. BMJ Open Respir Res. 2019;6(1):e000420.
doi:10.1136/bmjresp-2019-000420Francois B, Bellissant E, Gissot V, et al. 12-h pretreatment with methylprednisolone versus placebo for prevention of postextubation laryngeal oedema: a randomised double-blind trial. Lancet. 2007;369(9567):1083–1089.
doi:10.1016/S0140-6736(07)60526-1Aubier M, Murciano D, Lecocguic Y, et al. Effect of hypophosphatemia on diaphragmatic contractility in patients with acute respiratory failure. N Engl J Med. 1985;313(7):420–424.
doi:10.1056/NEJM198508153130705